October 21st 2016Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy
Girishanthy Krishnarajah, MPH, MBA/MS, PhD Jee-Yeon K. Lehmann, PhD Brian Ellman, MBA Rachel H. Bhak, MS Maral DerSarkissian, PhD Deane Leader, Jr, PhD, MBA Ann L. Bullinger, PharmD Mei